Join
Live feed
·
PRReleasevia Quantisnow
Atea Pharmaceuticals Inc. logo

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

ByQuantisnow·Wall Street's wire, on your screen.
AVIR· Atea Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AVIR (Atea Pharmaceuticals Inc.) and more on Quantisnow.